RxDoctor Payments DataLook up a doctor →

Paul Matherne, MD

Family Medicine · Gulfport, MSNPI 1730245739

Payments from drug & device makers

$14,436,038in general payments, 2019–2025

Across 3,487 payments — averaging $4139.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$6.7M
  • Modernatx, Inc.$2.9M
  • AstraZeneca$1.4M
  • Seqirus USA Inc$773K
  • GSK$597K
  • Boehringer Ingelheim$455K
  • plus $1.6M from 24 others
$1,131in research payments, 2019–2025

Across 4 payments — averaging $282.79 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$603
  • Modernatx, Inc.$528

What the payments were for

  • Travel & lodging$5,96364%
  • Food & beverage$3,37836%
  • Education$160%
  • Gifts$200%

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$14,436,038 in reported general payments places this provider in the 95th percentile of 971 family medicine providers in Mississippi.

See all family medicine providers in Mississippi

Medicare billing

Part B allowed, 2024
$86,028
Medicare patients
338
Services billed
1,152

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide106$131,618
JanuviaSitagliptin Phosphate68$59,733
TrulicityDulaglutide31$52,986
JardianceEmpagliflozin38$41,481
MyrbetriqMirabegron54$37,246
EliquisApixaban63$34,442
XareltoRivaroxaban36$28,423
FarxigaDapagliflozin Propanediol35$26,038
InvokanaCanagliflozin22$22,350
Tresiba Flextouch U-100Insulin Degludec11$15,273
MounjaroTirzepatide15$15,079
Victoza 3-PakLiraglutide12$14,401
RybelsusSemaglutide13$13,618
LinzessLinaclotide14$10,413
SymbicortBudesonide/Formoterol Fumarate29$8,651

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$149$145,236119 claims
MerckJanuvia$182,239$59,73368 claims
Johnson & JohnsonXarelto, Invokana$198,100$50,77358 claims
Boehringer IngelheimJardiance$455,228$41,48138 claims
PfizerEliquis, Premarin$6,719,396$39,20174 claims
Astellas Pharma US IncMyrbetriq$111$37,24654 claims
AstraZenecaFarxiga, Symbicort$1,423,787$34,68964 claims
AbbVieLinzess, Synthroid$682$15,10385 claims
GSKBreo Ellipta$596,893$6,26517 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$69$5,65012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 971 family medicine providers in Mississippi.

Other family medicine in Gulfport

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →